Role of the advanced glycation end products receptor in Crohn’s disease inflammation

Figure 6 Receptor for the advanced glycation end products expression at mucosal level. Immunoblotting of mucosal samples from both diseased and non-diseased areas of Crohn’s disease (CD) patients and from normal areas of control patients with the polyclonal anti-receptor for the advanced glycation end products (RAGE) antibody. The protein levels were measured by scanning densitometry as band area (A) and band intensity (B), expressed as arbitrary units, and normalized towards β-actin levels. In the upper part of both panels, representative cases of band area and intensity with respect to those of β-actin are shown. Specifically, the values for RAGE expression in diseased areas for both band area and band intensity were significantly higher (1.48 ± 0.16 and 1.64 ± 0.14, respectively) than those found in non-diseased areas (0.71 ± 0.40 and 0.66 ± 0.23, respectively) and healthy mucosa (0.44 ± 0.17 and 0.27 ± 0.15, respectively).